Clinical Trial Update: Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating disitamab vedotin plus radiotherapy as adjuvant treatment for HER2-expressing cisplatin-ineligible upper tract urothelial carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Peking University First Hospital | Conditions: Upper Tract Urothelial Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING